Intramammary expression and therapeutic effect of a human lysozyme-expressing vector for treating bovine mastitis.
To develop a gene therapy strategy for treating bovine mastitis, a new mammary-specific vector containing human lysozyme (hLYZ) cDNA and kanamycin resistance gene was constructed for intramammary expression and clinical studies. After one time acupuncture or intracisternal infusion of healthy cows with 400 microg of the p215C3LYZ vector, over 2.0 microg/ml of rhLYZ could be detected by enzymatic assay for about 3 weeks in the milk samples. Western blotting showed that rhLYZ secreted into milk samples from the vector-injected cows had molecular weight similar to that of the natural hLYZ in human colostrums. Twenty days after the primary injection, the quarters were re-injected with the same vector by quarter acupuncture and even higher concentrations of rhLYZ could be detected. Indirect competitive ELISA of milk samples showed that the vector injection did not induce detectable humoral immune response against hLYZ. Clinical studies showed that twice acupuncture of quarters with the p215C3LYZ vector had overt therapeutic effect on clinical and subclinical mastitis previously treated with antibiotics, including disappearance of clinical symptoms and relatively high microbiological cure rates. These data provide a solid rationale for using the vector to develop gene therapy for treating bovine mastitis.
Sun
Huai-chang
HC
School of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China. sun78564@hotmail.com
Xue
Fang-ming
FM
Qian
Ke
K
Fang
Hao-xia
HX
Qiu
Hua-lei
HL
Zhang
Xin-yu
XY
Yin
Zhao-hua
ZH
D026881:Acupuncture; D000818:Animals; D002417:Cattle; D005260:Female; D015316:Genetic Therapy / Q000379:methods / Q000662:veterinary*; D005822:Genetic Vectors / Q000235:genetics*; D008414:Mastitis, Bovine / Q000235:genetics* / Q000628:therapy*; D008892:Milk / Q000737:chemistry; D009113:Muramidase / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism
D009113:Muramidase